Pharmafile Logo
Pharmafocus logo
Advanced Search

Cancer

Showing 15 posts of 1067 posts found.

Avastin image

Avastin shows brain cancer benefit

November 20, 2012
Research and Development, Sales and Marketing Cancer, FDA, Merck, Roche, avastin, brain

In a Phase III trial, Roche’s Avastin has helped people with newly-diagnosed glioblastoma (GBM) live longer without their disease worsening. …

News

Patients ‘shut out’ of drug price talks

November 13, 2012
Sales and Marketing Cancer, NHS, NICE, VBP, prostate

Patients are being excluded from the negotiations between government and the pharma industry on the introduction of Value-Based Pricing (VBP).That …

News

Sanofi criticised for multiple sclerosis manoeuvres

November 2, 2012
Sales and Marketing Cancer, Lemtrada, MS, Sanofi

Sanofi is facing a backlash as it prepares its new MS treatment for the market. Lemtrada (alemtuzumab) has produced very …

News

J&J cancer drugs get EU approval

October 2, 2012
Sales and Marketing Cancer, Dacogen, EU, J&J, JJ, Velcade

Two of Johnson & Johnson’s key cancer drugs have been shown the green light from the European Commission. Janssen-Cilag International’s …

News
lilly corporate hq image

Lilly suffers late-stage cancer blow

September 10, 2012
Research and Development, Sales and Marketing Alimta, Cancer, avastin, lilly, oncology

Eli Lilly suffered a blow to its oncology programme when a new combination treatment failed to improve overall survival in …

News
merck kgaa image

Merck KGaA licences new cancer candidate

September 10, 2012
Research and Development, Sales and Marketing Cancer, EGFR, Merck KGaA, oncology

Merck KGaA has signed a worldwide licence agreement with Danish company Symphogen which could expand its portfolio of drugs targeting …

News
fda_sign_web

Double approval for Pfizer cancer drugs

September 6, 2012
Sales and Marketing CML, Cancer, Glivec, Pfizer, axitinib, rcc

 Two cancer drugs from Pfizer have been approved, one in Europe for kidney cancer and another in the US for …

News

Pfizer to develop phase II cancer vaccine

September 4, 2012
Research and Development, Sales and Marketing Cancer, Pfizer, VLST, cancer vaccine

Pfizer has licensed a cancer compound which is ready for phase II study from a US firm specialising in cancer …

News

J&J buys into Genmab cancer drug

August 31, 2012
Sales and Marketing Cancer, Genmab, Janssen Cilag, Janssen-Cilag, Johnson & Johnson, multiple myeloma

Danish biotech company Genmab has sold the worldwide rights for one of its cancer drugs to Johnson & Johnson-owned Janssen …

News

Novartis and Pennsylvania team up on cancer research

August 6, 2012
Research and Development Cancer, Novartis, University of Pennsylvania, chimeric antigen receptor

Novartis and the University of Pennsylvania have joined forces to investigate a method of treating cancer which encourages patients’ immune …

News
ariad_slideshow-3

Ariad touts next generation CML treatment

June 29, 2012
Research and Development, Sales and Marketing Ariad, CML, Cancer, Europe, Switzerland

Ariad Pharmaceuticals is to expand into Europe following promising results for an investigational cancer drug. The US biotech firm will …

News

DH admits cancer awareness campaigns failed

June 28, 2012
Sales and Marketing Cancer, Department of Health, GPs, government

The government’s £9 million cancer awareness campaigns were built upon failed pilots, according to newly released data. The national awareness …

News

Afinitor recommended in Europe for breast cancer

June 22, 2012
Sales and Marketing Afinitor, CHMP, Cancer, Novartis, breast

A European committee is recommending Novartis’ Afinitor to treat women with a certain type of breast cancer. The CHMP says …

News
Zytiga image

Janssen looks to broaden Zytiga licence

June 18, 2012
Sales and Marketing Cancer, Janssen, NICE, Provenge, Zytiga, prostate

Janssen is looking to broaden the licence for its prostate cancer pill Zytiga. Zytiga currently has a US and European …

News
Zelboraf image

Roche’s Zelboraf rejected by NICE

June 15, 2012
Sales and Marketing Cancer, Dillon, NICE, Roche, Zelboraf, melanoma

NICE is not recommending Roche’s targeted melanoma pill Zelboraf because of its high cost and uncertainties over its survival benefit. …

News
The Gateway to Local Adoption Series

Latest content

Just – Evotec given Gates Foundation grant to increase global biotherapeutics access

January 8, 2026

Johnson & Johnson submits robotic surgical system for De Novo classification

January 8, 2026

EA Pharma announces phase 3 trial for new schizophrenia treatment in Japan

January 7, 2026

Eleva appoints Erich Rajkovic as Chief Business Officer

January 7, 2026

MedPharm announces US FDA inspection of North Carolina manufacturing facility

January 6, 2026